VH-Fc ab8
A SARS-CoV-2 neutralizing VH antibody.
General information
VH-Fc ab8 represents a IgG1 heavy chain variable domain (VH) neutralizing SARS-CoV-2 (prepared using phage display technique with the SARS-CoV-2 spike protein RBD serving as the target) fused with human IgG1 crystallizable fragment (Fc) (Li et al., 2020).
Synonyms
VH Fc ab8
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models
Animal model In vitro Antibody |
Vero E6 cells; 293T cells; BALB/c mice; hamsters; Mouse ACE2 adapted SARS-CoV-2; SARS-CoV-2 (US_WA-1/2020) | 38.64 | The engineered antibody binds to the SARS-CoV-2 spike protein and its RBD with high affinity (higher than ACE2-Fc) and has potent neutralization capability in vitro. Mice that had been administered VH-Fc ab8 manifested effective inhibiton of SARS-CoV-2 (mice ACE2-adapted model). VH-Fc ab8 displayed both prophylactic and therapeutic efficacy in a hamster SARS-CoV-infection model, did not bind to human membrane proteins and did not form aggregates. |
Sep/04/2020 |
|
Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Spike protein ACE2 Spike variant Cryo-EM Biophysical assay In vitro Antibody |
in vitro biophysical assay; cryo-EM | 7.08 | The antibody bound and prevented ACE2-binding in the case of both wild type and N501Y Spike ectodomain variants. The VH-only version of the antibody was shown to bind RBD in both the “up” and “down” positions. |
Apr/29/2021 |
